Eli Lilly’s Obesity Drug Zepbound Reduces Sleep Apnea in Late-Stage Studies
The injection lowered obstructive sleep apnea severity by up to nearly two-thirds in obese adults, with and without PAP therapy, in two phase 3 trials.
Tag: clinical trials
All
Latest
All
Latest
Two-Thirds of Children Tolerate Peanut Protein After Omalizumab Treatment
The treatment yielded similar outcomes for egg, milk, wheat, cashew, walnut, and hazelnut.
All
Latest
Strategy to Fight Lung and Eye Diseases in Premature Infants
A study reveals that granulocyte colony-stimulating factor is a common pathological mechanism in both bronchopulmonary dysplasia and retinopathy of prematurity in premature infants, offering a new therapeutic target.
Can a New Minimally Invasive Procedure Cure Long-COVID Loss of Smell?
Researchers are finding success with a 10-minute minimally invasive procedure in trials to restore the sense of smell in long-COVID patients.
Read More
Cancer Surgeon Confirmed as New NIH Director
Monica M. Bertagnolli, MD, was installed as the 17th director of the National Institutes of Health, becoming the first surgeon and the second woman to hold the position.
Read More
Aileron Acquires Lung Therapeutics to Advance IPF Drug Candidate
Aileron Therapeutics acquired Lung Therapeutics Inc, a biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications.
Read More
Datopotamab Deruxtecan Improved NSCLC Survival
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumors, according to Phase 3 trial data.
Read More
Positive Data for Tagrisso in Patients with EGFR-mutated NSCLC
A Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) plus chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-free survival for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) and brain metastases at baseline.
Read More
Immune Cell Modification May Offer Improved Tuberculosis Defense
A Boston University-led research team has found a way to tweak immune cells to better fight tuberculosis, a method they say could lead to new treatments.
Read More
Investigational LYT-100 Shows Improved Tolerability Over Pirfenidone for IPF
New data presented at the CHEST Annual Meeting supports the improved tolerability of LYT-100 over FDA-approved pirfenidone and provides insights into dose selection.
Read More
High-dose Inhaled Nitric Oxide Aids COVID-19 Respiratory Failure
A phase 2 study showed the treatment improved blood oxygen levels and lowered the risk of long-term sensory and motor neurologic symptoms.
Read More
Transplanting COPD Patients’ Own Cells Restores Lung Function
Researchers have shown it is possible to repair damaged lung tissue in patients with chronic obstructive pulmonary disease using the patients’ own lung cells.
Read More
Arthritis Drug Abatacept Tested for Early Immune Modulation in Mild COVID-19
Part of NIH’s STRIVE consortium, the therapeutic may prevent overactive immune systems from causing severe symptoms.
Read More
NIH Trial of Six-Strain Universal Flu Vaccine Candidate Begins
The nanoparticle vaccine candidate, FluMos-v2, builds on its predecessor FluMos-v1 and is designed to induce antibodies against six flu strains.
Read More
Idrevloride in Hypertonic Saline Boosts Lung Function in Primary Ciliary Dyskinesia Patients
A new study finds that idrevloride in hypertonic saline is safe and associated with a significant improvement in lung function in individuals with primary ciliary dyskinesia when compared to hypertonic saline alone.
Read More